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Objectives: Trimethoprim (TMP)/sulfamethoxazole (SMX) has consistently demonstrated great interin-
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concentration has been proposed as 100 to 150 μg/mL. The objective of our work was to determine the
success rate of a TMP/SMX dosing guideline in achieving a targeted serum peak SMX concentration range.
Methods: Our retrospective cohort study enrolled 305 adult hospitalized patients who received treatment
with TMP/SMX and underwent serum peak SMX concentration monitoring from January 2003 to November
2011. Patients receiving low-dose TMP/SMX therapy (TMP o15 mg/kg/d) were compared with those
receiving high-dose therapy (TMP 415 mg/kg/d).
Results: Patients were classiﬁed into peak and modiﬁed peak SMX concentration cohorts based on time
between TMP/SMX dose and SMX quantiﬁcation. The association between dosing group and the outcome of
the SMX level within the goal range was measured using logistic regression models. The primary outcome
measured was serum peak SMX concentration 100 to 150 μg/mL. Serum peak SMX concentrations were
attained within range for the peak and modiﬁed peak cohort 29% and 26% of the time, respectively. The
median peak SMX concentration was 144 μg/mL (range 25–471 μg/mL). The low daily dose cohort
demonstrated a trend toward improvement in the odds of target peak concentration range attainment.
The results were similar regardless of the method used to adjust for baseline characteristics. The pure peak
and modiﬁed peak cohorts had 44% and 46% of patients with above-target SMX peak concentrations,
respectively.
Conclusions: Attainment of the intended target concentration range was low with no difference in
attainment between the low-dose and high-dose cohorts. Higher proportions of patients had an above-
target SMX peak, which may indicate that the dosing algorithm is overly aggressive in obtaining the
therapeutic goal.
& 2014. The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).Introduction
Trimethoprim (TMP)/sulfamethoxazole (SMX) is a broad-
spectrum antimicrobial combination effective in treating a variety
of microorganisms and has been used in clinical practice for more
than 50 years.1 High response rates demonstrated in clinical
studies support TMP/SMX as the drug of choice for serious
infections such as Stenotrophomonas maltophilia, Pneumocystis
jiroveci, and Nocardia spp.2–4,5Inc. This is an open access article u
D, Department of Pharmacy
55905.
eto).Since its discovery, pharmacokinetic studies of TMP/SMX serum
concentrations have consistently demonstrated great interindivid-
ual variability6,7 and the use of therapeutic drug monitoring was
attempted to optimize clinical efﬁcacy while minimizing adverse
effects.7–9 Hughes et al10 determined low peak SMX concentration
was associated with treatment failure in a study of 55 randomized
pediatric patients with Pneumocystis carinii pneumonia (PCP
pneumonia) and proposed 100 to 150 μg/mL as the optimal
therapeutic range based on concentrations assayed from the 26
patients assigned to the TMP/SMX arm combined with any levels
drawn from patients who crossed between treatments. This
therapeutic range was further investigated for clinical efﬁcacy in
a study of treatment for AIDS-associated PCP pneumonia in
HIV-positive adult patients, of whom 21 were assigned to receivender the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Table I
Trimethoprim/sulfamethoxazole dosing algorithm.*
Creatinine clearance High dose Low dose
Z30 mL/min 15–20 mg/kg/d in
3–4 divided doses
o15 mg/kg/d in
2–4 divided doses
o30 mL/min† 7–10 mg/kg/24 h in
2 divided doses
o7 mg/kg/24 h
divided q12h–q24h
n Dose based on trimethoprim component.
† Patients receiving dialysis were recommended to receive the dose indicated
for patients with CrCl o 30 ml/min with the dose scheduled after dialysis on
dialysis days.
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previous studies with a high rate of TMP/SMX-related adverse
events.7 Additionally, peak SMX concentrations 4200 μg/mL
demonstrated an association with severe adverse effects.9,11,12
Despite extensive clinical experience, difﬁculties remain in achiev-
ing the proposed therapeutic SMX peak serum concentration of
100 to 150 μg/mL.8 The limited data surrounding a relationship
between peak SMX serum concentrations and clinically mean-
ingful outcomes call into question the use of routine therapeutic
drug monitoring during high-dose TMP/SMX therapy.
The use of TMP/SMX therapy at our institution is frequently
coupled with therapeutic drug monitoring in an effort to attain a
targeted SMX peak serum concentration. Our institutional dosing
algorithm has not been veriﬁed for its accuracy of attainment of
the prespeciﬁed peak serum SMX concentration goal of 100 to 150
μg/mL. The purpose of our study is to compare the performance of
a TMP/SMX dosing algorithm in achieving targeted serum peak
SMX concentrations in hospitalized patients who received ther-
apeutic doses of TMP/SMX.Materials and Methods
Eligible patients
This single-center, retrospective cohort study was approved by
the Mayo Clinic Institutional Review Board and conducted at Mayo
Clinic in Rochester, Minnesota. Consecutive adult patients who
received therapeutic doses of TMP/SMX between January 2003
and November 2011 were evaluated. Patients were included if they
were aged 18 years or older and underwent serum peak SMX
monitoring during TMP/SMX therapy. Intravenous or oral admin-
istration was allowed due to the nearly complete bioavailability of
the oral formulations.13 Patients were excluded if they received
TMP/SMX for infection prophylaxis, underwent TMP/SMX desen-
sitization, or had the serum SMX plasma concentration monitored
outside of their hospitalization. Data collection was limited to the
earliest chronologic occurrence of therapeutic TMP/SMX admin-
istration with concurrent therapeutic drug monitoring for the
purposes of maintaining independent data. Only the ﬁrst peak
serum SMX concentration was considered during this evaluation.
Laboratory assessment
SMX serum concentration levels were determined by HPLC by
our institution’s Clinic Toxicology and Drug Monitoring Laboratory.14
Deﬁnitions
The goal peak SMX concentration range of 100 to 150 μg/mL
was deﬁned per our institution’s antimicrobial therapy guide.15
Serum SMX concentrations were considered peak concentrations
if they were measured between 1 and 2 hours after intravenous
administration or between 2 and 3 hours after administration of
an oral dose at the onset of steady-state conditions.15 Serum SMX
concentrations were considered modiﬁed peak if they were
measured within 4 hours after intravenous administration and
within 5 hours of oral administration. The peak values in the
modiﬁed peak group served as surrogate peak levels in the
absence of multilevel sampling and pharmacokinetic estimation.
The peak and modiﬁed peak cohorts were categorized into 2 dos-
ing groups—high dose or low dose—according to our institution’s
dosing algorithm for the prespeciﬁed subgroup analysis (Table I).
The high-dose group received a total daily dose Z15 mg/kg actual
body weight of the TMP component. The low-dose group received
a total daily dose o15 mg/kg actual body weight of the TMPcomponent. The dosing intervals ranged from every 6 hours to
every 24 hours, depending on the patient’s creatinine clearance
(Table I).16,17 Patients were assessed for dosage adjustments based
on estimated creatinine clearance using the Cockcroft-Gault
formula.18
Data collection
Clinical and demographic data were retrospectively abstracted
from medical records and divided into 3 categories: demographic
data, infectious disease data, and TMP/SMX data. Demographic
data included age, sex, body weight, serum creatinine, estimated
creatinine clearance calculated by the Cockcroft-Gault formula,
and absence/presence of preexisting chronic kidney disease or
immunocompromised status as documented in electronic medical
records before the date of admission. Additionally, chronic kidney
disease was veriﬁed through a search for ICD-9-CM and ICD-10-CM
diagnosis codes for chronic kidney disease (585 and N18, respec-
tively). Infectious disease data included site of infection and infec-
tious organism. Lastly, TMP/SMX data included TMP/SMX start date
and time; TMP/SMX dose (milligrams per kilogram TMP compo-
nent); and interval, date, time, and value of peak serum peak SMX
concentration. The primary outcome measured was the frequency of
serum peak SMX concentration within the deﬁned goal of 100 to
150 μg/mL.
Statistical analysis
Variables were summarized as median (range or interquartile
range) or frequency (%), as appropriate. Baseline comparisons
between high- and low-dose groups were done using the Wil-
coxon rank-sum test for continuous variables or Pearson χ2 test for
discrete variables. To adjust for possible covariate imbalance
between the high- and low-dose groups, propensity scores of the
probability of receiving a high dose were computed for each
patient using a multivariable logistic regression model that
included variables for chronic kidney disease, dialysis, immuno-
compromised status, intensive care unit admission, pulmonary
diagnosis, identiﬁed infectious organism (eg, Stenotrophomonas
maltophilia, Pneumocystis jiroveci, Nocardia spp, Staphylococcus spp,
or polymicrobial), body mass index (BMI), and creatinine clear-
ance.19 The association between dosing group and the outcome of
the SMX level being within the therapeutic range was measured
using 4 different logistic regression models: including only the
dose group as a predictor (unadjusted model), including the dose
group and all the variables that went into the propensity score
computation (standard covariate adjustment model), including the
dose group and the propensity score as a covariate (propensity
score covariate adjustment model), and model stratiﬁed by pro-
pensity score quintile groups with a predictor of dose group
(propensity score stratiﬁed model). Models 2 through 4 adjust
for the covariates, but in different ways. Model 1 is provided for
B.D. Dao et al. / Current Therapeutic Research 76 (2014) 104–109106comparison to assess the level of covariate adjustment. An odds
ratio with 95% CI for being in range, comparing the high- and low-
dose groups, is provided for each model. These 4 models are ﬁt for
2 different cohorts. The ﬁrst cohort consisted of patients with SMX
levels that were measured during the pure peak period. The
second cohort included patients who had a SMX level measured
during the pure peak period or the modiﬁed peak period.Results
One thousand four hundred sixty-three individual serum SMX
concentrations were recorded from 686 patients between January
2003 and November 2011. Of these, a total of 381 patients met our
inclusion and exclusion criteria (Figure 1). From the 381 patients,
76 patients were excluded because the serum SMX concentration
was taken outside the modiﬁed peak window, leaving 305 patients
for analysis in the modiﬁed peak group and 119 patients for
analysis in the peak group (Figure 1).
Peak group
The peak group consisted of 119 patients with 82 patients in
the low-dose group and 37 patients in the high-dose group.
Baseline characteristics of the peak cohort are shown in Table II
and Table III. The median age was 65.2 years (interquartile range
¼ 53.8–74.9 years) and the majority (90%) were immunocompro-
mised. Most patients experienced a pulmonary infection (70%)
with Stenotrophomonas maltophilia (32%) and Pneumocystis carinii
(36%) as the predominant causative organisms. Baseline character-
istics were similar between patients when comparing the low- andPatients with a sulfamethoxazole concentration drawn during TMP/SMX
(n = 686)
Excluded
Insufficient data (n = 145)
Outpatient status (n = 96)
TMP/SMX as prophylaxis (n = 48)
No research consent (n = 10)
Age <18 y (n = 10)
Desensitization required (n = 1)
Outside modified peak timeframe (n = 76)
Modified peak group
(n = 305)
High dose modified peak group
(n = 110)
Low dose modified peak group
(n = 195)
Peak group
(n = 119)
Low dose peak group
(n = 82)
High dose peak group
(n = 39)
Excluded
Outside peak timeframe (n = 186)
Figure 1. Consort diagram. TMP/SMX ¼ trimethoprim/sulfamethoxazole.high-dose groups except for BMI and type of infection. The
low-dose group members were found to have a higher median
BMI compared with members of the high-dose group (25.3 vs 23.0,
respectively; P ¼ 0.01).
Overall, 28.6% of patients were found to be within the ther-
apeutic range on the ﬁrst peak SMX concentration. For the
remaining patients, 27.7% were below the target and 43.7% were
above the target. The median SMX concentration was 144 μg/mL
(range ¼ 25–471 μg/mL). Median time from the start of TMP/SMX
therapy to the ﬁrst level was 2 days (range ¼ 1–32 days). The low-
dose group had 32% of patients within the therapeutic range,
whereas the high-dose group had 22% of patients within the target
range (Table IV). In the peak cohort, 31.5% of those receiving oral
dosing (23 out of 73 patients) were in range compared with 23.9%
of those receiving intravenous dosing (11 out of 46 patients)
(P ¼ 0.37 by Pearson χ2 test). The propensity score analysis
revealed no statistical differences between the 2 dosing groups
in regard to therapeutic concentration range attainment. Compar-
ison of the dosing groups showed consistent results across all the
multiple propensity score models (Table V).Modiﬁed peak group
The modiﬁed peak group consisted of 305 patients with 195
categorized as receiving a low dose and 110 as receiving a high
dose (Figure 1). The median age within the cohort was 63.6 years.
Comparison of the baseline characteristics between the 2 dosing
arms showed statistically signiﬁcant higher frequencies of patients
with diabetes (P ¼ 0.0014) and patients undergoing dialysis
(P ¼ 0.033) in the low-dose group (Table II). Additionally, the
low dose group had a higher BMI compared with the high-dose
group (P ¼ 0.0355). The high-dose group was characterized by
more immunocompromised patients (P ¼ 0.0005) and more
patients with higher creatinine clearance (P ¼ 0.0010).
The attainment in the modiﬁed peak group had 26% of patients
within the therapeutic range on the ﬁrst peak SMX concentration.
The remaining patients were found to be below the target 29% of
the time and above the target 46% of the time. A higher proportion
of patients within the low-dose group was in the therapeutic range
(28%) compared with the high-dose group (22%). The modiﬁed
peak cohort had a median peak SMX concentration of 144 μg/mL
(range ¼ 25–471 μg/mL). Median time from the start of TMP/SMX
therapy to the ﬁrst level in the modiﬁed peak cohort was 2 days
(range ¼ 0–32 days). In the modiﬁed peak cohort, 27.6% of those
receiving oral dosing (34 out of 123 patients) were in range
compared with 24.2% of those (44 out of 182 patients) receiving
intravenous dosing (P ¼ 0.50 by Pearson χ2 test). The propensity
score matching analyses demonstrated no difference in therapeu-
tic attainment between the 2 dosing arms (Table V). The results
were unchanged regardless of the method.Discussion
TMP/SMX is a commonly prescribed antimicrobial agent for the
treatment of many different infections. Our institution commonly
pairs TMP/SMX with therapeutic drug monitoring for serious
infections such as Stenotrophomonas maltophilia, Pneumocystis
jiroveci, and Nocardia spp. The results of our study demonstrate
that our institution’s dosing algorithmwas unsuitable to attain the
suggested goal therapeutic range for the majority of patients
(71.4%) in the peak cohort. Additionally, peak SMX concentrations
exhibited high variability despite weight-based dosing adjusted
for renal function whereby a majority of the results in the peak
cohort (44%) were above the target.
Table II
Baseline demographic characteristics.
Characteristic Peak (n ¼ 119) Modiﬁed peak (n ¼ 305)
Total
Low-dose
(n ¼ 82)
High-dose
(n ¼ 37) P Total
Low-dose
(n ¼ 195)
High-dose
(n¼ 110) P
Male gender* 82 (68.9) 55 (67.1) 27 (73.0) 0.52 208 (68.2) 134 (68.7) 74 (67.3) 0.79
Age† 65.2 (53.8–74.0) 64.5 (53.8–74.1) 68.2 (54.8–72.8) 0.91 63.6 (49.8–72.6) 64.6 (53.5–74.1) 60.7 (45.5–69.4) 0.0067
Race*
White 102 (85.7) 71 (86.6) 31 (83.8) 0.6860 260 (85.2) 167 (85.6) 93 (84.5) 0.7956
Hispanic 2 (1.7) 2 (2.4) 0 (0) 4 (1.3) 4 (2.1) 0 (0)
African American 1 (0.8) 1 (1.2) 0 (0) 2 (0.7) 2 (1.0) 0 (0)
Asian/Paciﬁc Islander 0 (0) 0 (0) 0 (0) 2 (0.7) 0 (0) 2 (1.8)
Native American 0 (0) 0 (0) 0 (0) 1 (0.3) 1 (0.5) 0 (0)
Other/not reported 14 (11.8) 8 (9.8) 6 (16.2) 36 (11.8) 21 (10.8) 15 (13.6)
Weight† (kg) 74.0 (63.3–85.8) 75.1 (65.8–87.7) 71.5 (60.4–79.8) 0.058 75.4 (63.4–88.1) 74.8 (64.6–90.0) 73.3 (61.1–84.5) 0.087
Body mass index† 24.8 (21.5–27.9) 25.3 (22.0–29.7) 23.0 (20.3–25.1) 0.011 25.0 (21.9–29.2) 25.4 (22.7–30.1) 24.6 (21.5–27.9) 0.036
Creatinine clearance‡ 68.4 (44.9–97.6) 65.3 (37.5–95.9) 78.5 (52.0–106.8) 0.065 69.8 (46.3–103.3) 64.1 (39.6–94.1) 78.0 (53.2–110.5) 0.001
Comorbidities
Chronic kidney disease* 25 (21.0) 17 (20.7) 8 (21.6) 0.91 62 (20.3) 42 (21.5) 20 (18.3) 0.48
Dialysis* 17 (14.3) 15 (18.3) 2 (5.4) 0.063 42 (13.8) 33 (16.9) 9 (8.2) 0.033
Hemodialysis 11 (9.2) 11 (13.4) 0 (0) 27 (8.9) 22 (11.3) 5 (4.5)
Continuous venovenous
hemoﬁltration
6 (5.0) 4 (4.9) 2 (5.4) 15 (4.9) 11 (5.6) 4 (3.6)
Diabetes* 30 (25.2) 24 (29.3) 6 (16.2) 0.13 70 (23.0) 56 (28.7) 14 (12.7) 0.0014
Immunocompromised* 107 (89.9) 71 (86.6) 36 (97.3) 0.073 267 (87.5) 161 (82.6) 106 (96.4) 0.0005
n Values are given as n (%).
† Values are given as median (interquartile range).
‡ Values are given as median (mL/min).
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concentrations may be unavoidable in clinical practice. There are
numerous clinical situations, such as procedures or imaging
studies, that may impede the proper timing of laboratory serum
draws. For this reason, we further described a modiﬁed peak
cohort to account for varying clinical situations and the time frame
for peak serum SMX concentration was extended to within 4 hours
after intravenous administration and within 5 hours after oral
administration. The extension of the peak time window was
performed to better represent real clinical practice. Regardless of
the allowed time frame of serum peak SMX concentration quanti-
ﬁcation, the 2 dosing regimens we evaluated did not have any
signiﬁcant inﬂuence on the rate of target range attainment.Table III
Microbiology characteristics.*
Characteristic Peak (n ¼ 119)
Total Low-dose (n ¼ 82) High-dose (n ¼ 37
Site of infection
Central nervous system 1 (0.8) 1 (1.2) 0 (0.0)
Intra-abdominal 6 (5.0) 5 (6.1) 1 (2.7)
Pulmonary 83 (69.7) 55 (67.1) 28 (75.7)
Bone 5 (4.2) 4 (4.9) 1 (2.7)
Skin, soft tissue 1 (0.8) 1 (1.2) 0 (0.0)
Urine 1 (0.8) 1 (1.2) 0 (0.0)
Bloodstream 6 (5.0) 4 (4.9) 2 (5.4)
Empiric therapy 15 (12.6) 10 (12.2) 5 (13.5)
Multifocal infection 1 (0.8) 1 (1.2) 0 (0.0)
Organism
Stenotrophomonas maltophilia 40 (33.6) 32 (39.0) 8 (21.6)
Pneumocystis (carinii) jiroveci 43 (36.1) 20 (24.4) 23 (62.2)
Empiric therapy 15 (12.6) 10 (12.2) 5 (13.5)
Other† 21 (17.6) 20 (24.4) 1 (2.7)
N/A, not applicable.
n Values are given as n (%).
† Other organisms include Staphylococcus spp: methicillin-sensitive Staphylococcus au
(peak n ¼ 1, modiﬁed peak n ¼ 1), Staphylococcus epidermidis (peak n ¼ 1, modiﬁed p
‡ Based on the combination of all organism groups within each cohort.The modiﬁed peak cohort was consistent in results returning
above the target range (46%).
Interestingly, the low-dose group did show a trend of higher
tendency to achieve the target range but this was not found to be
statistically signiﬁcant in all of the propensity score models. The
results were consistent across the unadjusted and adjusted propen-
sity score models, strengthening the result of no signiﬁcant differ-
ence between the high- and low-dose groups for attainment of
therapeutic peak SMX concentrations. Despite no apparent differ-
ence in attainment rates, the pure peak and modiﬁed peak cohorts
had 44% and 46% of patients with above-target SMX peak concen-
trations, respectively. This may indicate that the dosing algorithm is
overly aggressive in regard to obtaining a goal-directed range.Modiﬁed peak (n ¼ 305)
) P Total Low-dose (n ¼ 195) High-dose (n¼ 110) P
N/A N/A
2 (0.7) 2 (1.0) 0 (0.0)
11 (3.6) 10 (5.1) 1 (0.9)
194 (63.6) 120 (61.5) 74 (67.3)
9 (3.0) 8 (4.1) 1 (0.9)
8 (2.6) 8 (4.1) 0 (0.0)
1 (0.3) 1 (0.5) 0 (0.0)
23 (7.5) 15 (7.7) 8 (7.3)
54 (17.7) 29 (14.9) 25 (22.7)
3 (1.0) 2 (1.0) 1 (0.9)
0.0002‡ o0.0001‡
104 (34.1) 88 (45.1) 16 (14.5)
108 (35.4) 47 (24.1) 61 (55.5)
53 (17.4) 28 (14.4) 25 (22.7)
40 (13.1) 32 (16.4) 8 (7.3)
reus (peak n ¼ 1, modiﬁed peak n ¼ 1), methicillin-resistant Staphylococcus aureus
eak n ¼ 2) and Nocardia spp (peak n ¼ 12, modiﬁed peak n ¼ 21).
Table IV
Therapeutic attainment.*
Value of peak sulfamethoxazole
concentration
Peak cohort Modiﬁed peak cohort
Overall (n ¼ 119) Low dose (n ¼ 82) High dose (n ¼ 37) Overall (n ¼ 305) Low dose (n ¼ 195) High dose (n ¼ 110)
Below target (o100 μg/mL) 33 (27.7) 32 (39.0) 1 (2.7) 91 (28.8) 85 (43.6) 6 (5.5)
Target (100-150 μg/mL) 34 (28.6) 26 (31.7) 8 (21.6) 75 (25.6) 52 (26.7) 23 (20.9)
Above target (4150 μg/mL) 52 (43.7) 24 (29.3) 28 (75.7) 139 (45.6) 58 (29.7) 81 (73.6)
n Values are given as n (%).
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studies that have shown high interindividual variability of SMX
in regard to plasma concentrations.6,12 The peak SMX concentra-
tions in our study are similar to serum levels of SMX reported in
other clinical studies.6,16,17 Remarkable interpatient variability was
shown by Blaser et al6 in a study of high-dose TMP/SMX in PCP
pneumonia where TMP/SMX was dosed at 15 to 22 mg/kg/d of the
TMP component and resulted in a median peak SMX concentration
of 198 μg/mL with multiple patients found to have concentrations
4300 μg/mL. Many studies have attempted to establish a relation-
ship between TMP/SMX dose and resultant serum concentration
without success; however, these studies were limited by small
sample size.12,20–22 High variability has been seen despite con-
trolled administration and weight-speciﬁc dosing without a cor-
relation to TMP, SMX, or N-acetyl-SMX.6 Another study showed no
correlation between serum creatinine and plasma concentrations.
As a renally eliminated antimicrobial agent, even subclinical
changes in glomerular ﬁltration rate (GFR) may signiﬁcantly alter
the plasma concentrations of TMP/SMX. Unfortunately, clinically
applicable bedside surrogates of renal function incompletely
reﬂect true GFR.23–25 Serum creatinine in speciﬁc is affected by
age, sex, race, and habitus. Furthermore, TMP itself alters serum
creatinine concentrations (therefore altering creatinine clearance)
independent of changing true GFR. Drug-induced inhibition of the
renal tubular secretion of creatinine results in an artiﬁcial increase
in serum creatinine concentrations and an underestimation of true
GFR by creatinine clearance. Lastly, recent evidence suggests that
contemporary methods of renal replacement substantially
removes TMP/SMX, leading to below-target SMX concentrations
and a potential need for revised dosing in this population.26,27 In
the peak cohort, 16.7% were within range while receiving hemo-
dialysis, whereas 27.3% achieved the target range while receiving
continuous venovenous hemoﬁltration. In the modiﬁed peak
cohort, 20% were in range while receiving hemodialysis, whereas
22.2% were in range while receiving continuous venovenous
hemoﬁltration. Unfortunately, the numbers of patients receiving
dialysis were too few to allow any inferences about being in range
within dialysis subgroups. All of these factors likely contribute to
the challenges of accurate renal function interpretation in theseTable V
Logistic regression models comparing the high- to low-dose groups for therapeutic
attainment.
Cohort Odds ratio (95% CI) P
Peak cohort
Statistical model
Unadjusted 0.594 (0.239–1.477) 0.26
Standard covariate adjustment 0.864 (0.282–2.650) 0.80
Propensity score covariate adjustment 0.852 (0.285–2.543) 0.77
Propensity score stratiﬁed 0.793 (0.268–2.350) 0.68
Modiﬁed peak cohort
Unadjusted 0.729 (0.420–1.264) 0.26
Standard covariate adjustment 0.681 (0.358–1.293) 0.24
Propensity score covariate adjustment 0.650 (0.348–1.212) 0.18
Propensity score stratiﬁed 0.67 (0.363–1.263) 0.22patients and the signiﬁcant interindividual variability noted in
our study.
Chin et al28 found similar attainment rates in their investigation
of the inﬂuence of monitoring serum TMP/SMX concentrations in
patients with PCP pneumonia. TMP/SMX was dosed at 20 mg/kg/d
of the TMP component with an intended goal peak SMX concen-
tration range of 150 to 200 μg/mL. Dose adjustments were
performed in the intervention arm to improve the therapeutic
range attainment; however, researchers demonstrated that only
28% of SMX concentrations in the dose-adjustment group were
within the therapeutic range compared with 32% without adjust-
ment. Despite the higher established target therapeutic range, the
results were similar to our study’s attainment of 26% within the
therapeutic range.
There are a number of limitations to our study. First is the
potential for selection bias given the single-center, retrospective
nature of our study design. Our patient population consisted of a
majority of white, male patients. The enrollment of patients
consecutively during the study period and implementation of the
propensity score matching method were our attempt to minimize
the effects of confounding variables when comparing the low- and
high-dose groups. The peak SMX concentrations from both oral
and intravenous administration were combined for analysis, which
may lead to difﬁculties in interpretation. Peak SMX concentrations
were combined from 2 different routes of administration because
of oral administration results in almost complete absorption.
Analysis demonstrated similar distribution of levels between
different routes of administration. Further, there was no statistical
difference in target concentration attainment when comparing the
intravenous versus oral route (24% and 27%, respectively). Third,
therapeutic drug monitoring of serum peak SMX levels are
obtained at the physicians’ and pharmacists’ discretion as opposed
to following a standardized algorithm; however, the median time
of 2 days of administration before concentration quantiﬁcation
ensured that SMX levels were drawn at steady state concentra-
tions. The potential for drug accumulation after the time at which
steady state occurs may augment the already high percentage of
patients in the above-target classiﬁcation and make our analysis
an overestimation of patients within the target range. Daily
processing and reporting of serum peak SMX concentrations by
our institution’s laboratory allows dose adjustments to occur in a
timely fashion if necessary; however, routine laboratory monitor-
ing is not available in all institutions so real-time laboratory
assessment may be a challenge.
To our knowledge, this study represents the largest reported
sample to date of TMP/SMX monitoring. This study adds to the
literature on therapeutic drug monitoring of SMX currently cen-
tered on Pneumocystis jiroveci pneumonia treatment and provides
a robust set of patients using therapeutic drug monitoring of peak
SMX concentrations for various infections requiring TMP/SMX
therapy. In addition, including a modiﬁed peak cohort allows our
results to be applicable to routine clinical practice. Clinical out-
comes were not assessed in our study, but our results establish a
foundation to support further assessment of the inﬂuence of
SMX concentrations on the efﬁcacy and safety of the high doses
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heterogeneity of the indications for using TMP/SMX treatment
and the low attainment rates of goal-directed therapeutic SMX
concentrations, further prospective, randomized studies are
needed to elucidate the optimal dose of TMP/SMX, further deﬁne
the ideal goal therapeutic ranges for Nocardia spp and Stenotro-
phomonas maltophilia infections, and investigate the association of
peak SMX concentration and clinical outcomes.Conclusions
Peak SMX concentrations demonstrate wide variability, result-
ing in low overall attainment of intended target concentration
ranges. There was no difference in attainment between the low-
and high-dose cohorts. Therapeutic range attainment rates were
poor regardless of administration of high- or low-dose TMP/SMX.
Higher proportions of patients had an above-target SMX peak,
which may be an indication that the dosing algorithm is overly
aggressive in regard to obtaining the therapeutic goal. The wide
therapeutic index of TMP/SMX coupled with the broad range of
resultant serum concentrations makes targeted therapy difﬁcult
and of questionable necessity. Further investigation into the
association between peak SMX concentration monitoring and
clinically meaningful outcomes, including treatment response
and adverse effects, should be conducted in larger, prospective
clinical trials with a more diverse patient population.Acknowledgments
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